|
n
|
93,522
|
11,955
|
105,477
|
|
Malea
|
50,963 (55)
|
7,609 (64)
|
58,572 (56)
|
|
Age at diagnosis (years)b
|
60 (13)
|
68 (11)
|
61 (13)
|
|
Patients by year of diagnosisa
|
|
1990–December 1999
|
1,893 (2)
|
201 (2)
|
2,094 (2)
|
|
January 2000–December 2004
|
28,551 (31)
|
3,741 (31)
|
32,292 (31)
|
|
January 2005–December 2009
|
52,317 (56)
|
6,647 (56)
|
58,964 (56)
|
|
January 2010
|
10,761 (12)
|
1,366 (11)
|
12,127 (12)
|
|
Smoking statusa
|
|
Current smoking
|
17,545 (19)
|
2,022 (17)
|
19,567 (19)
|
|
Ex-smoking
|
39,016 (42)
|
6,922 (58)
|
45,938 (44)
|
|
BMI at diagnosis (kg/m2)b
|
32 (7)
|
31 (6)
|
32 (7)
|
|
HbA1c at diagnosis (%)b
|
8.2 (2.2)
|
7.8 (2.0)
|
8.1 (2.2)
|
|
HbA1c at diagnosis (mmol/mol)b
|
66
|
62
|
65
|
|
HbA1C ≥7% (≥53 mmol/mol) post diagnosisa
|
|
Consistently during 1 year post diagnosis
|
27,375 (29)
|
3,096 (26)
|
30,471 (29)
|
|
Consistently during 2 years post diagnosis
|
20,856 (22)
|
2,245 (19)
|
23,101 (22)
|
|
CVE during follow-upa
|
|
MI
|
1,876 (2.01)
|
569 (4.76)
|
2,445 (2.32)
|
|
HF
|
2,295 (2.45)
|
898 (7.51)
|
3,193 (3.03)
|
|
Stroke
|
1,782 (1.91)
|
485 (4.06)
|
2,267 (2.15)
|
|
Any CVE
|
4,293 (6.64)
|
1,833 (8.39)
|
6,126 (7.08)
|
|
Renal diseasea
|
|
Before diagnosis
|
16,630 (17.78)
|
3,116 (26.06)
|
19,746 (18.72)
|
|
Post diagnosis
|
25,662 (27.44)
|
4,601 (38.49)
|
30,263 (28.69)
|
|
Duration of follow-up (years)c
|
5.0 (3.4, 7.2)
|
5.4 (3.5, 7.7)
|
5.3 (3.5, 7.7)
|
|
Medicationa
|
|
2 OADs
|
41,696 (45)
|
4,515 (38)
|
46,211 (44)
|
|
Insulin
|
8,778 (9)
|
1,004 (8)
|
9,782 (9)
|
|
OAD + insulin
|
8,380 (9)
|
954 (8)
|
9,334 (9)
|
|
Intensified treatment
|
44,042 (45)
|
4,012 (56)
|
48,036 (46)
|
